BioCryst Pharmaceuticals, Inc., headquartered in Durham, North Carolina, specializes in developing oral small-molecule and protein therapeutics for hereditary angioedema and other rare diseases. The company focuses on innovative treatments in the rare disease pharmaceutical sector, demonstrating domain expertise in specialized therapeutic development.

‌